Status:
UNKNOWN
Effects of Radioactive Iodine on the Immune System in Thyroid Cancer
Lead Sponsor:
Radboud University Medical Center
Conditions:
Thyroid Carcinoma, Nonmedullary
Eligibility:
All Genders
18+ years
Brief Summary
Blood will be drawn 1 month before and 2 month after regular radioactive iodine treatment. Monocytes will be isolated. The three main outcomes are whole blood counts, cytokine production upon in vitro...
Detailed Description
Earlier studies have shown that, particularly advanced, thyroid carcinomas are highly immunogenic tumors. The immune system is involved in both pathogenesis and progression of thyroid carcinoma (TC), ...
Eligibility Criteria
Inclusion
- Pathologically confirmed non-medullary thyroid cancer
- Undergoing radioactive iodine treatment in an adjuvant setting or for persistent structural disease
- Aged ≥ 18 years
Exclusion
- Inflammatory or infectious comorbidities
- Using medication interfering with the immune system
- Pregnancy
- A self-reported alcohol consumption of \>21 units per week
- Other active malignancies, defined as malignancies not in complete remission for \<2 years
- Previous systemic anti-cancer treatment such as chemotherapy, targeted therapy, radiotherapy or immunotherapy within 3 years before study procedures
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05989555
Start Date
January 1 2024
End Date
December 1 2025
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Medical Center
Nijmegen, Netherlands